ArticleInfection and immunity2002
Construction of an Actinobacillus pleuropneumoniae serotype 2 prototype live negative-marker vaccine.
Article in Infection and immunity, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Review of advanced research on swineFrontiers in immunology · 2025Review
- Comparative Efficacy in Challenge Dose Models of a Toxin Expressing Whole-Cell Vaccine against Eight Serovars ofAnimals : an open access journal from MDPI · 2022Article
- Link between Heterotrophic Carbon Fixation and Virulence in the Porcine Lung Pathogen Actinobacillus pleuropneumoniae.Infection and immunity · 2019Article
- Immunoprotective Efficacy of SixFrontiers in microbiology · 2016Article
- Pathway deregulation and expression QTLs in response to Actinobacillus pleuropneumoniae infection in swine.Mammalian genome : official journal of the International Mammalian Genome Society · 2014Article
- Identification of QTL affecting resistance/susceptibility to acute Actinobacillus pleuropneumoniae infection in swine.Mammalian genome : official journal of the International Mammalian Genome Society · 2014Article
- Article
- Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice.Journal of veterinary science · 2007Article
- Use of an Actinobacillus pleuropneumoniae multiple mutant as a vaccine that allows differentiation of vaccinated and infected animals.Infection and immunity · 2006Article
- Deletion of the anaerobic regulator HlyX causes reduced colonization and persistence of Actinobacillus pleuropneumoniae in the porcine respiratory tract.Infection and immunity · 2005Article
- Enzymes involved in anaerobic respiration appear to play a role in Actinobacillus pleuropneumoniae virulence.Infection and immunity · 2005Article
- Characterization of the antigenic lipopolysaccharide O chain and the capsular polysaccharide produced by Actinobacillus pleuropneumoniae serotype 13.Infection and immunity · 2004Article
- Identification of dimethyl sulfoxide reductase in Actinobacillus pleuropneumoniae and its role in infection.Infection and immunity · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deletions were introduced into the ureC and apxIIA genes of an Actinobacillus pleuropneumoniae serotype 2 strain by homologous recombination and counterselection. The double-mutant contains no foreign DNA, is highly attenuated, protects pigs from homologous challenge upon a single aerosol application, and facilitates the serological discrimination of immunized and infected herds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.